We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02579044
Recruitment Status : Enrolling by invitation
First Posted : October 19, 2015
Last Update Posted : September 2, 2022
Information provided by (Responsible Party):
Monica E. Kleinman, Boston Children's Hospital

Brief Summary:
This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.

Condition or disease Intervention/treatment Phase
Progeria Drug: Everolimus and lonafarnib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Study Start Date : December 2015
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023

Arm Intervention/treatment
Everolimus and Lonafarnib
Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
Drug: Everolimus and lonafarnib

Primary Outcome Measures :
  1. Maximum-tolerated dose (MTD) of everolimus when administered orally in combination with lonafarnib in subjects with progeria [ Time Frame: 12 Months ]
    For Phase I portion of protocol

  2. Number and type of dose-limiting toxicities when everolimus and lonafarnib are administered in combination to children with progeria [ Time Frame: 12 Months ]
    For Phase I portion of protocol

  3. Annual increase in weight gain [ Time Frame: 24 Months ]
    For Phase II portion of protocol

  4. Change in pulse wave velocity (PWV) [ Time Frame: 24 months ]
    For Phase II portion of protocol

Secondary Outcome Measures :
  1. Markers of progeria-specific activity [ Time Frame: 24 Months ]
    For Phase II portion of protocol

  2. Trough levels of everolimus in combination with lonafarnib in progeria [ Time Frame: 12 months ]
    For Phase I portion of protocol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Months to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Genetically-confirmed progeria.
  • display clinical signs of progeria as per the clinical trial team.
  • currently receiving lonafarnib under protocol 09-06-0298
  • have not experienced a grade 3 or 4 toxicity within two months preceding enrollment
  • willing and able to come to Boston for appropriate studies and examinations.
  • no recent fractures or major surgery (within four weeks)
  • Absolute poly count (Absolute neutrophil count + bands + monocytes) >1,000/uL
  • platelets >75,000/uL (transfusion independent)
  • hemoglobin >9 g/dL
  • creatinine ≤ 1.5 times upper limit of normal (ULN) for age or Glomerular filtration rate (GFR) >70 mL/min/1.73m2
  • bilirubin ≤ 1.5x upper limit of normal for age
  • SGPT (ALT) < and SGOT (AST) ≤ 2.5x normal range for age
  • serum albumin greater than or equal to 2 g/dL
  • PT/PTT: INR <1.3 (or <3 on anticoagulants)
  • Fasting LDL cholesterol within 1.5x ULN per institutional guidelines (ie, <195 mg/dL for 2 - 18 years of age, <240 mg/dL for subjects >18 years old)* and Fasting serum cholesterol <300 mg/dL (<7.75 mmol/L)* and Fasting triglycerides <2.5 ULN (<325 mg/dL for ages 2 - 18, <400 for ages >18)*

    *may be re-evaluated for eligibility after initiation of lipid-lowering therapy

  • Signed informed consent according to institutional guidelines must be obtained and subject must begin therapy within twenty-eight (28) days.

Exclusion Criteria:

  • Subjects must not be taking medications that significantly affect the metabolism of lonafarnib
  • Subjects receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary. Topical or inhaled steroids are allowed.
  • Subjects who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug; have not recovered from the side effects of any major surgery (defined as requiring general anesthesia but excluding a procedure for insertion of central venous access); or who may require major surgery during the course of the study.
  • 13.2.5 Subjects with an active bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin).
  • Subjects who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • known severely impaired lung function
    • active (acute or chronic) or uncontrolled severe infections.
    • liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
    • History of hepatitis B or hepatitis C
  • Other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration).
  • A known history of Human Immunodeficiency Virus (HIV) seropositivity or known immunodeficiency.
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A nasogastric tube (NG tube) or gastric tube (G tube) is allowed.
  • Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
  • Subjects must not be pregnant or breast-feeding. Female subjects of childbearing potential must have negative serum or urine pregnancy test. Sexually active male and female subjects of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female subjects to take oral contraceptives or other hormonal methods while receiving treatment with everolimus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02579044

Layout table for location information
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children's Hospital
Layout table for investigator information
Principal Investigator: Monica Kleinman, M.D. Boston Children's Hospital
Layout table for additonal information
Responsible Party: Monica E. Kleinman, Medical Director, Transport & MSICU, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT02579044    
Other Study ID Numbers: P00017505
First Posted: October 19, 2015    Key Record Dates
Last Update Posted: September 2, 2022
Last Verified: September 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metabolic Diseases
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action